Sensus Healthcare Appoints Megan Cornish to its Board of Directors

Gains valuable Capitol Hill, business strategy and marketing experience

BOCA RATON, Fla, Nov. 05, 2020 (GLOBE NEWSWIRE) -- Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for oncological and non-oncological conditions, announces the appointment of Megan Cornish to its board of directors, effective January 1, 2021. Ms. Cornish’s appointment will expand the number of directors to six.

Ms. Cornish brings to Sensus more than a decade of experience working on Capitol Hill in several Congressional offices and as a lobbyist advising a broad range of companies in a variety of industries. Since 2016 she has served as vice president of external affairs and corporate secretary for FoodMaven Corporation, a Colorado Springs-based company that sells unsold and oversupplied food from distributors, manufacturers and producers to restaurants and institutional buyers. Since 2013 she has been an independent consultant to corporations, law firms, not-for-profit organizations and political campaigns on government relations and lobbying.

Ms. Cornish served from 2012 to 2013 as Legislative Assistant to Rep. Tim Holden of Pennsylvania, who was a member of the U.S. Committee on Agriculture from 1992 to 2014. From 2009 to 2012 while serving as Legislative Assistant to Rep. Edolphus Towns of New York, she researched and analyzed immigration, science and technology, homeland security, animal rights issues and special projects while he served as Chairman of the U.S. House Committee on Oversight and Government Reform. Earlier in her career she contributed to multiple political campaigns for candidates running for local, state and federal offices.

“Megan is an in-demand business leader capable of solving complex problems and developing actionable strategies that lead to success, and we are fortunate to welcome her to the Sensus board of directors,” said Joe Sardano, Sensus Healthcare’s chairman and chief executive officer. “We have worked with Megan over the years and know she can open doors on Capitol Hill and nationwide to raise awareness for superficial radiation therapy and gain support from regulatory agencies. In addition, her communication and marketing expertise will provide fresh thinking as we expand awareness among physicians and patient groups, particularly regarding the use of SRT to prevent keloid recurrence following surgical excision. The appointment of Megan to the board achieves a long-time goal of bringing an individual with a different and diverse perspective to our leadership team. Megan is a great complement to our existing board members.”

Commenting on her board appointment, Ms. Cornish said, “Sensus Healthcare provides an important, efficacious and non-invasive treatment for non-melanoma skin cancer and keloids that more people deserve access to. I believe in Joe Sardano and his team and am excited to leverage my experience and contacts to help breakdown regulatory barriers so that this innovative treatment is more widely available.”

Ms. Cornish received a B.A. in political science from Colorado College and an M.A. in global security from Johns Hopkins University.

About Sensus Healthcare

Sensus Healthcare, Inc. is a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for both oncological and non-oncological conditions. The Sculptura™ modulated robotic brachytherapy radiation oncology system provides targeted directional anisotropic radiation therapy (ART) and brachytherapy utilizing our proprietary, state-of-the-art 3D Beam Sculpting™ to treat patients undergoing cancer treatment during surgery, or at the tumor site, fast and efficiently. Sensus also offers its proprietary low-energy X-ray technology known as superficial radiation therapy (SRT), which is the culmination of more than a decade of research and development, to treat non-melanoma skin cancers and keloids with its SRT-100™, SRT-100+™ and SRT-100 Vision™ systems. With its portfolio of innovative medical device products, Sensus provides revolutionary treatment options to enhance the quality of life of patients around the world.

For more information, visit www.sensushealthcare.com.

Forward-Looking Statements

This press release includes statements that are, or may be deemed, ‘’forward-looking statements.’’ In some cases these forward-looking statements can be identified by the use of forward-looking terminology including “believes,” “estimates,” “anticipates,” “expects,” “plans,” “intends,” “may,” “could,” “might,” “will,” “should,” “approximately,” “potential” or, in each case, their negative or other variations thereon or comparable terminology, although not all forward-looking statements contain these words.

By their nature, forward-looking statements involve risks and uncertainties because they relate to events, competitive dynamics and healthcare, regulatory and scientific developments, and depend on the economic circumstances that may or may not occur in the future or may occur on longer or shorter timelines than anticipated. Although we believe that we have a reasonable basis for each forward-looking statement contained in this press release, we caution you that forward-looking statements are not guarantees of future performance and that our actual results of operations, financial condition and liquidity, and the development of the industry in which we operate may differ materially from the forward looking statements contained in this press release, as a result of, among other factors: the continuation and severity of the COVID-19 pandemic, including its impact on sales and marketing; our ability to achieve and sustain profitability; market acceptance of our product lines; our ability to successfully commercialize our products; our ability to compete effectively in selling our products and services, including responding to technological change and cost containment efforts of our customers; our need and ability to obtain additional financing in the future; our ability to expand, manage and maintain our direct sales and marketing organizations; our ability to obtain and maintain intellectual property of sufficient scope to adequately protect our products, and our ability to avoid infringing or otherwise violating the intellectual property rights of third parties; the willingness of healthcare providers to purchase our products if coverage, reimbursement and pricing from third party payors for procedures using our products declines; the level and availability of government and third party payor reimbursement for clinical procedures using our products; our ability to effectively manage our anticipated growth, including hiring and retaining qualified personnel; the regulatory requirements applicable to us and our competitors; our ability to manufacture our products to meet demand; our current reliance on third party manufacturers and sole- or single-source suppliers, as well as our ability to successfully transition manufacturing of our products in-house; our ability to reduce the per unit manufacturing costs; our ability to efficiently manage our manufacturing processes; the regulatory and legal risks, and certain operating risks, that our international operations subject us to; the fact that product quality issues or product defects may harm our business; the accuracy of our financial statements and accounting estimates, including allowances for accounts receivable and inventory obsolescence; any product liability claims; new legislation, administrative rules, or executive orders, including those that impact taxes and international trade regulation; concentration of our customers in the U.S. and China, including the concentration of sales to one particular customer in the U.S.; and other risks described from time to time in Sensus Healthcare’s filings with the Securities and Exchange Commission, including our Annual Report on Form 10-K.

In addition, even if our results of operations, financial condition and liquidity, and the development of the industry in which we operate are consistent with the forward-looking statements contained in this press release, they may not be predictive of results or developments in future periods. Any forward-looking statements that we make in this press release speak only as of the date of such statement, and we undertake no obligation to update such statements to reflect events or circumstances after the date of this press release. You should read carefully our “Cautionary Note Regarding Forward-Looking Information” and the factors described in the “Risk Factors” section of our periodic reports filed with the Securities and Exchange Commission to better understand the risks and uncertainties inherent in our business.

Contact:
LHA Investor Relations
Kim Sutton Golodetz
212-838-3777
kgolodetz@lhai.com

# # #

Primary Logo

Back to news